期刊文献+

噬菌体肽库在宫颈癌血清肿瘤标志物筛选中的应用 被引量:4

Application of phage display peptide library in screening of the tumor markers in the serum of cervical cancer
下载PDF
导出
摘要 目的:用噬菌体随机12肽库对宫颈癌患者血清进行差异性筛选,筛选出能与宫颈癌患者血清特异性结合的肿瘤标志物。方法:应用噬菌体随机12肽库对宫颈癌患者和正常人血清进行三轮差异性筛选,用ELISA法检测噬菌体克隆对宫颈癌患者血清结合的特异性。结果:经过三轮筛选,噬菌体富集率逐轮提高,提高近100倍。用ELISA法对50例宫颈癌患者血清和50例健康者血清检测验证,其中获得一株与宫颈癌患者血清特异结合较好的噬菌体,对宫颈癌的早期诊断具有潜在价值。结论:筛选出能与早期宫颈癌患者血清高亲和力特异结合的短肽,为研究宫颈癌肿瘤标志物及宫颈癌的早期诊断奠定了基础。 Objective: To find the new specific tumor marker for breast cancer through screening the phage display peptide library in the serum of patients with cervical cancer. Methods: Three rounds of subtract biopanning were carried out. ELISA was used to confirm the specificity of phages clones. Results: After three rounds of screening,the enrichment ratio was increased. The eluted were enrich to 100 fold. The phage with high specificity was found and confirm in the serum of 50 cases of cervical cancer patients and normal people by ELISA. It have potential value for early diagnosis of cervical cancer. Conclusion: A high affinity dodecapeptide specific for the serum of cervical cancer was obtained through phage display library. It can be used for the next step in tumor marker of cervical cancer and early diagnosis of cervical cancer.
出处 《现代肿瘤医学》 CAS 2015年第7期908-910,共3页 Journal of Modern Oncology
基金 广西科技厅基金项目(编号:0991232)
关键词 宫颈癌 噬菌体肽库 肿瘤标志物 cervical cancer phage peptide library tumor marker
  • 相关文献

参考文献2

二级参考文献41

  • 1卫生部肿瘤防治研究办公室.中国恶性肿瘤死亡调查研究[M].北京:人民卫生出版社,1979,1..
  • 2Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008,Cancer Incidence and Mortality Worldwide : IARC CancerBase, 2010,10. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc, fr [ 2011-08-11 ].
  • 3Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control, 1997,8( 5 ) : 755-763.
  • 4Gustafsson L, Ponten J, Bergstrom R, et al. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer, 1997,71(2) : 159-165.
  • 5Belinson J, Qiao YL, Pretorius R, et al. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol, 2001,83(2) :439-444.
  • 6Goldie S J, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA, 2001,285 (24) : 3107- 3115.
  • 7Myers ER,Mccrory DC,Nanda K,et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol, 2000, 151 (12) : 1158- 1171.
  • 8Andres-Gamboa O, Chicaiza L, Garcia-Molina M, et al. Cost- effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex, 2008, 50(4) :276-285.
  • 9Perkins RB,Langrish SM,Stern LJ, et al. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues, 2010,20( 1 ) : 35-42.
  • 10Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med, 1997,102(5A): 3-8.

共引文献363

同被引文献31

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部